EGFR-mutant lung adenocarcinomas mutation profiles reveal ARID1A might be a novel tyrosine kinase resistance pathway

被引：0
|
作者：
Gao, Xuyuan [1 ]
Xu, Hang [2 ]
Ho, James C. M. [3 ]
Chan, Oscar S. H. [4 ]
Xu, Feng [5 ]
Wang, Junwen [6 ]
Lee, Victor H. F. [7 ]
Tin, Vicky P. C. [1 ]
Xiao, Zhijie [1 ]
Wang, Siqi [1 ]
Yam, Judy W. P. [1 ]
Wong, Maria P. [1 ]
机构：
[1] Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China
[2] Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China
[3] Univ Hong Kong, Dept Med, Hong Kong, Peoples R China
[4] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[5] Univ British Columbia, St Pauls Hosp, Providence Hlth Care, Vancouver, BC, Canada
[6] Mayo Clin, Scottsdale, AZ USA
[7] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-LB-196
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-196
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
    Yu, Helena A.
    Tian, Shaozhou K.
    Drilon, Alexander E.
    Borsu, Laetitia
    Riely, Gregory J.
    Arcila, Maria E.
    Ladanyi, Marc
    JAMA ONCOLOGY, 2015, 1 (07) : 981 - 983
  • [32] Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
    Aboubakar Nana, Frank
    Ocak, Sebahat
    PHARMACEUTICS, 2021, 13 (09)
  • [33] Acquired Resistance to EGFR Tyrosine Kinase Inhibitors is Associated With Low Efficacy of Radiation Therapy for Brain Metastases From EGFR-mutant Lung Adenocarcinoma
    Hirata, H.
    Nakamura, K.
    Kunitake, N.
    Shioyama, Y.
    Sasaki, T.
    Nonoshita, T.
    Inoue, K.
    Nagashima, A.
    Ono, M.
    Honda, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S102 - S102
  • [34] Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.
    Yu, Helena Alexandra
    Sima, Camelia S.
    Drilon, Alexander Edward Dela Cruz
    Varghese, Anna M.
    Pietanza, Maria Catherine
    Azzoli, Christopher G.
    Rizvi, Naiyer A.
    Krug, Lee M.
    Kris, Mark G.
    Miller, Vincent A.
    Riely, Gregory J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
    Shi, Xuefei
    Zhou, Jia
    Qian, Caihua
    Gao, Liliang
    Wang, Bin
    Feng, Xueren
    ONCOTARGETS AND THERAPY, 2020, 13 : 6789 - 6793
  • [36] Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability
    Wu, D-W
    Chen, C-Y
    Chu, C-L
    Lee, H.
    ONCOGENE, 2016, 35 (05) : 621 - 630
  • [37] Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
    Elkrief, Arielle
    Makhnin, Alex
    Moses, Khadeja A.
    Ahn, Linda S.
    Preeshagul, Isabel R.
    Iqbal, Afsheen N.
    Hayes, Sara A.
    Plodkowski, Andrew J.
    Paik, Paul K.
    Ladanyi, Marc
    Kris, Mark G.
    Riely, Gregory J.
    Michor, Franziska
    Yu, Helena A.
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1423 - 1428
  • [38] Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability
    D-W Wu
    C-Y Chen
    C-L Chu
    H Lee
    Oncogene, 2016, 35 : 621 - 630
  • [39] RAS signaling pathway gene mutations and acquired resistance to EGFR tyrosine-kinase inhibitors in EGFR mutant lung cancer
    Ohashi, Kadoaki
    Chmielecki, Juliann
    Lin, Ya-Lun
    Pan, Helen
    Vnencak-Jones, Cindy
    Arcila, Maria
    Wang, Lu
    Fernandez, Lynnette
    Keisuke, Aoe
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Toyooka, Shinichi
    Kiura, Katsuyuki
    Thomas, Roman
    Yang, James Chih-Hsin
    Miller, Vincent
    Ladanyi, Marc
    Politi, Katerina
    Pao, William
    CANCER RESEARCH, 2012, 72
  • [40] Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
    Yu, Helena A.
    Suzawa, Ken
    Jordan, Emmet
    Zehir, Ahmet
    Ni, Ai
    Kim, Ryan
    Kris, Mark G.
    Hellmann, Matthew D.
    Li, Bob T.
    Somwar, Romel
    Solit, David B.
    Berger, Michael F.
    Arcila, Maria
    Riely, Gregory J.
    Ladanyi, Marc
    CLINICAL CANCER RESEARCH, 2018, 24 (13) : 3108 - 3118
12345